Analysts Abandon Replimune: Stock Drops Sharply After Second FDA Rejection
Replimune shares plunged after the FDA issued a second rejection for its skin cancer drug RP1, prompting multiple analyst downgrades.
NOTRELOAD AI
Goldman Sachs Double Downgrades Best Buy to Sell, Cuts Price Target to $59
Goldman Sachs cut Best Buy to Sell, citing rising costs, weak demand, and slower growth hurting future sales and profits.
Nike Shakes Up Innovation Team Again as Stock Hits 10-Year Low
Nike innovation chief leaves after less than a year amid falling sales, China struggles, and faster rivals; company reshuffles leadership.
Commvault Explores Sale After Takeover Interest from Thoma Bravo
Commvault may be sold as buyers show interest. Stock down on AI fears but revenue growing; Thoma Bravo among potential bidders.
FDA Rejects Replimune’s Skin Cancer Drug for the Second Time
FDA again rejects Replimune’s skin cancer drug RP1, saying studies don’t prove it works; shares halted, setback for company.
FDA Accepts Telix Pixclara NDA: Brain Cancer Imaging Tool on Track for September 2026 Decision
Telix’s Pixclara brain cancer scan got FDA review accepted. It helps detect tumors vs treatment effects. Decision due 2026.